When selecting between topical roflumilast and topical corticosteroids for seborrheic dermatitis in an area with a high actinic keratosis burden, could choosing a PDE4 inhibitor like roflumilast theoretically deliver a beneficial anti-neoplastic field effect while simultaneously clearing the patient's seborrheic dermatitis?

When treating seborrheic dermatitis over fields of severe facial actinic damage, the choice of topical therapy presents a unique clinical dilemma: Traditional topical corticosteroids have effective anti-inflammatory properties, and their localized immunosuppressive properties raise theoretical concerns regarding the disruption of cutaneous immune surveillance within a pre-neoplastic microenvironment of actinic keratoses (AK). However, according to FDA-approved clinical trial data and labeling, PDE4 inhibitors (roflumilast) carry no known risk of accelerating non-melanoma skin cancers (NMSC). A recent publication by Khodadad et al., PMID 42144714, noted that PDE4 inhibition influences mechanisms beyond simple visual clearance, potentially modulating keratinocyte and fibroblast cellular senescence, accelerating skin barrier recovery, and fostering localized regulatory immune homeostasis via increased IL-10 and Treg activity. Therefore, could choosing a PDE4 inhibitor like roflumilast theoretically deliver a beneficial anti-neoplastic field effect while simultaneously clearing the patient's seborrheic dermatitis?